joining chain of multimeric IgA and IgMGenealiases: IGCJ · IGJ · JCH
Q-omics provides the consensus-scored JCHAIN profile across patient tissues and cancer cell-line models. JCHAIN expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, JCHAIN is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, JCHAIN protein abundance shows 20,450 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where JCHAIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JCHAIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JCHAIN survival associations across molecular data types. JCHAIN RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JCHAIN RNA expression–survival associations across cancer types. High JCHAIN expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, BRCA, LUAD and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for JCHAIN RNA expression.
This table summarizes JCHAIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for JCHAIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JCHAIN shows lower tumor expression in COAD, LIHC, LUSC, BRCA and KICH and higher tumor expression in KIRC. The COAD box plot shows higher JCHAIN RNA expression in normal versus tumor tissue (log2 FC = −5.531, t-test p < 0.001).
This table shows molecular features associated with JCHAIN in patient tissues and cancer cell lines. In patient samples, JCHAIN shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, JCHAIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
